New Two-Drug attack on Tough-to-Treat Hodgkin's lymphoma
NCT ID NCT05355051
Summary
This study is testing whether combining two existing drugs, pembrolizumab and azacitidine, can help control Hodgkin's lymphoma that has returned or hasn't responded to other treatments. It will measure how well the combination shrinks tumors and how safe it is for patients, including children as young as 1 year old. The goal is to see if this approach can help patients achieve a response, potentially allowing them to proceed to a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.